Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—a clinical pilot study

BackgroundMyalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) entails low quality of life for patients and massive societal costs. There is an urgent need for elucidation of disease mechanisms and for rational treatment. Our working hypothesis is that ME/CFS in a subgroup of patients is asso...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Øystein Fluge, Ingrid Gurvin Rekeland, Kari Sørland, Kine Alme, Kristin Risa, Ove Bruland, Karl Johan Tronstad, Olav Mella
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2025-07-01
Serija:	Frontiers in Medicine
Teme:	ME/CFS clinical trial daratumumab autoantibodies plasma cell feasibility pathomechanism
Online dostop:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1607353/full
Oznake:	Označite Brez oznak, prvi označite!